Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

Racial Disparities in Clinically Significant Prostate Cancer Treatment: The Potential Health Information Technology Offers.

Bickell NA, Lin JJ, Abramson SR, Hoke GP, Oh W, Hall SJ, Stock R, Fei K, McAlearney AS.

J Oncol Pract. 2018 Jan;14(1):e23-e33. doi: 10.1200/JOP.2017.025957. Epub 2017 Dec 1.

PMID:
29194001
2.

Atypical Diabetic Foot Ulcer Keratinocyte Protein Signaling Correlates with Impaired Wound Healing.

Hoke GD, Ramos C, Hoke NN, Crossland MC, Shawler LG, Boykin JV.

J Diabetes Res. 2016;2016:1586927. Epub 2016 Oct 20.

3.

Disseminated Balamuthia mandrillaris Infection.

Schafer KR, Shah N, Almira-Suarez MI, Reese JM, Hoke GM, Mandell JW, Roy SL, Visvesvara G.

J Clin Microbiol. 2015 Sep;53(9):3072-6. doi: 10.1128/JCM.01549-15. Epub 2015 Jul 1.

4.

Using discriminant analysis to determine sources of salinity in shallow groundwater prior to hydraulic fracturing.

Lautz LK, Hoke GD, Lu Z, Siegel DI, Christian K, Kessler JD, Teale NG.

Environ Sci Technol. 2014 Aug 19;48(16):9061-9. doi: 10.1021/es502244v. Epub 2014 Aug 1.

PMID:
25062431
5.

Considering Factors of and Knowledge About Patients in Handover Assessment.

Meth S, Bass EJ, Hoke G.

IEEE Trans Hum Mach Syst. 2013 Sep 1;43(5):494-498.

6.

Bringing technology to the bedside: using smartphones to improve interprofessional communication.

Whitlow ML, Drake E, Tullmann D, Hoke G, Barth D.

Comput Inform Nurs. 2014 Jul;32(7):305-11. doi: 10.1097/CIN.0000000000000063.

PMID:
24784489
7.

Use of an appreciative inquiry approach to improve resident sign-out in an era of multiple shift changes.

Helms AS, Perez TE, Baltz J, Donowitz G, Hoke G, Bass EJ, Plews-Ogan ML.

J Gen Intern Med. 2012 Mar;27(3):287-91. doi: 10.1007/s11606-011-1885-4. Epub 2011 Oct 14.

8.

Association of HPC2/ELAC2 and RNASEL non-synonymous variants with prostate cancer risk in African American familial and sporadic cases.

Robbins CM, Hernandez W, Ahaghotu C, Bennett J, Hoke G, Mason T, Pettaway CA, Vijayakumar S, Weinrich S, Furbert-Harris P, Dunston G, Powell IJ, Carpten JD, Kittles RA.

Prostate. 2008 Dec 1;68(16):1790-7. doi: 10.1002/pros.20841.

9.

Epidemiology of benign prostatic hyperplasia and comorbidities in racial and ethnic minority populations.

Hoke GP, McWilliams GW.

Am J Med. 2008 Aug;121(8 Suppl 2):S3-10. doi: 10.1016/j.amjmed.2008.05.021. Review.

PMID:
18675615
10.

Rise of the Andes.

Garzione CN, Hoke GD, Libarkin JC, Withers S, MacFadden B, Eiler J, Ghosh P, Mulch A.

Science. 2008 Jun 6;320(5881):1304-7. doi: 10.1126/science.1148615.

PMID:
18535236
11.

Discontinuity of care: further thoughts on standardized processes.

Enfield KB, Hoke G.

J Hosp Med. 2007 Mar;2(2):115-6; author reply 116-7. No abstract available.

PMID:
17427985
12.

Racial differences in pathogenetic mechanisms, prevalence, and progression of benign prostatic hyperplasia.

Hoke G, Baker W, Barnswell C, Bennett J, Davis R, Mason T, Rayford W.

Urology. 2006 Nov;68(5):924-30. Review. No abstract available.

PMID:
17113881
13.

Genome-wide linkage of 77 families from the African American Hereditary Prostate Cancer study (AAHPC).

Baffoe-Bonnie AB, Kittles RA, Gillanders E, Ou L, George A, Robbins C, Ahaghotu C, Bennett J, Boykin W, Hoke G, Mason T, Pettaway C, Vijayakumar S, Weinrich S, Jones MP, Gildea D, Riedesel E, Albertus J, Moses T, Lockwood E, Klaric M, Faruque M, Royal C, Trent JM, Berg K, Collins FS, Furbert-Harris PM, Bailey-Wilson JE, Dunston GM, Powell I, Carpten JD.

Prostate. 2007 Jan 1;67(1):22-31.

PMID:
17031815
14.

A common nonsense mutation in EphB2 is associated with prostate cancer risk in African American men with a positive family history.

Kittles RA, Baffoe-Bonnie AB, Moses TY, Robbins CM, Ahaghotu C, Huusko P, Pettaway C, Vijayakumar S, Bennett J, Hoke G, Mason T, Weinrich S, Trent JM, Collins FS, Mousses S, Bailey-Wilson J, Furbert-Harris P, Dunston G, Powell IJ, Carpten JD.

J Med Genet. 2006 Jun;43(6):507-11. Epub 2005 Sep 9.

15.

Molecular characterization of suicide by microarray analysis.

Gwadry FG, Sequeira A, Hoke G, Ffrench-Mullen JM, Turecki G.

Am J Med Genet C Semin Med Genet. 2005 Feb 15;133C(1):48-56. Review.

PMID:
15645524
16.

Clinical characteristics of African-American men with hereditary prostate cancer: the AAHPC Study.

Ahaghotu C, Baffoe-Bonnie A, Kittles R, Pettaway C, Powell I, Royal C, Wang H, Vijayakumar S, Bennett J, Hoke G, Mason T, Bailey-Wilson J, Boykin W, Berg K, Carpten J, Weinrich S, Trent J, Dunston G, Collins F.

Prostate Cancer Prostatic Dis. 2004;7(2):165-9.

PMID:
15175665
17.

African-American heredity prostate cancer study: a model for genetic research.

Powell IJ, Carpten J, Dunston G, Kittles R, Bennett J, Hoke G, Pettaway C, Weinrich S, Vijayakumar S, Ahaghotu CA, Boykin W, Mason T, Royal C, Baffoe-Bonnie A, Bailey-Wilson J, Berg K, Trent J, Collins F.

J Natl Med Assoc. 2001 Apr;93(4):120-3.

18.

African-American heredity prostate cancer study: a model for genetic research.

Powell IJ, Carpten J, Dunston G, Kittles R, Bennett J, Hoke G, Pettaway C, Weinrich S, Vijayakumar S, Ahaghotu CA, Boykin W, Mason T, Royal C, Baffoe-Bonnie A, Bailey-Wilson J, Berg K, Trent J, Collins F.

J Natl Med Assoc. 2001 Dec;93(12 Suppl):25S-28S.

19.

Recruitment experience in the first phase of the African American Hereditary Prostate Cancer (AAHPC) study.

Royal C, Baffoe-Bonnie A, Kittles R, Powell I, Bennett J, Hoke G, Pettaway C, Weinrich S, Vijayakumar S, Ahaghotu C, Mason T, Johnson E, Obeikwe M, Simpson C, Mejia R, Boykin W, Roberson P, Frost J, Faison-Smith L, Meegan C, Foster N, Furbert-Harris P, Carpten J, Bailey-Wilson J, Trent J, Berg K, Dunston G, Collins F.

Ann Epidemiol. 2000 Nov;10(8 Suppl):S68-77.

PMID:
11189095
20.

Prostate carcinoma knowledge, attitudes, and screening behavior among African-American men in Central Harlem, New York City.

Ashford AR, Albert SM, Hoke G, Cushman LF, Miller DS, Bassett M.

Cancer. 2001 Jan 1;91(1):164-72.

PMID:
11148573
21.

Picture perfect. Cost-effective solutions help advanced medical imaging make business sense.

Hoke GE.

Healthc Inform. 1999 Apr;16(4):89-90, 92, 94-6. No abstract available.

PMID:
10538425
22.

The influence of gender on incidence and outcome of patients with bladder cancer in Harlem.

Hoke GP, Stone BA, Klein L, Williams KN.

J Natl Med Assoc. 1999 Mar;91(3):144-8.

23.

2',5'-linked oligo-3'-deoxyribonucleoside phosphorothioate chimeras: thermal stability and antisense inhibition of gene expression.

Bhan P, Bhan A, Hong M, Hartwell JG, Saunders JM, Hoke GD.

Nucleic Acids Res. 1997 Aug 15;25(16):3310-7.

24.
25.

Antisense gene suppression against human ICAM-1, ELAM-1, and VCAM-1 in cultured human umbilical vein endothelial cells.

Lee CH, Chen HH, Hoke G, Jong JS, White L, Kang YH.

Shock. 1995 Jul;4(1):1-10.

PMID:
7552771
26.

(2'-5')-Oligo-3'-deoxynucleotides: selective binding to single-stranded RNA but not DNA.

Alul R, Hoke GD.

Antisense Res Dev. 1995 Spring;5(1):3-11.

PMID:
7542046
27.

The presence of peptidoglycan-polysaccharide complexes in the bowel wall and the cellular responses to these complexes in Crohn's disease.

Klasen IS, Melief MJ, van Halteren AG, Schouten WR, van Blankenstein M, Hoke G, de Visser H, Hooijkaas H, Hazenberg MP.

Clin Immunol Immunopathol. 1994 Jun;71(3):303-8.

PMID:
7515336
28.

Glycoprotein of human immunodeficiency virus type 1 synthesized in chronically infected Molt3 cells acquires heterogeneous oligosaccharide structures.

Pal R, di Marzo Veronese F, Nair BC, Rittenhouse S, Hoke G, Mumbauer S, Sarngadharan MG.

Biochem Biophys Res Commun. 1993 Nov 15;196(3):1335-42.

PMID:
8250888
29.

Antisense oligodeoxynucleotides: synthesis, biophysical and biological evaluation of oligodeoxynucleotides containing modified pyrimidines.

Sanghvi YS, Hoke GD, Freier SM, Zounes MC, Gonzalez C, Cummins L, Sasmor H, Cook PD.

Nucleic Acids Res. 1993 Jul 11;21(14):3197-203.

30.
31.

Characterization of a neutralizing monoclonal antibody to the external glycoprotein of HIV-1.

Pal R, di Marzo Veronese F, Nair BC, Rahman R, Hoke G, Mumbauer SW, Sarngadharan MG.

Intervirology. 1992;34(2):86-93.

PMID:
1284059
32.

Effects of phosphorothioate capping on antisense oligonucleotide stability, hybridization and antiviral efficacy versus herpes simplex virus infection.

Hoke GD, Draper K, Freier SM, Gonzalez C, Driver VB, Zounes MC, Ecker DJ.

Nucleic Acids Res. 1991 Oct 25;19(20):5743-8.

33.

Brefeldin A inhibits the processing and secretion of envelope glycoproteins of human immunodeficiency virus type 1.

Pal R, Mumbauer S, Hoke GM, Takatsuki A, Sarngadharan MG.

AIDS Res Hum Retroviruses. 1991 Aug;7(8):707-12.

PMID:
1718346
34.

Effect of Evans blue and trypan blue on syncytia formation and infectivity of human immunodeficiency virus type I and type II in vitro.

Pal R, Mumbauer S, Hoke G, Larocca R, Myers C, Sarngadharan MG, Stein CA.

AIDS Res Hum Retroviruses. 1991 Jun;7(6):537-43.

PMID:
1718343
36.

Mode of action of 5'-linked cholesteryl phosphorothioate oligodeoxynucleotides in inhibiting syncytia formation and infection by HIV-1 and HIV-2 in vitro.

Stein CA, Pal R, DeVico AL, Hoke G, Mumbauer S, Kinstler O, Sarngadharan MG, Letsinger RL.

Biochemistry. 1991 Mar 5;30(9):2439-44.

PMID:
1705817
37.

In vivo development and in vitro characterization of a subclone of murine P388 leukemia resistant to bis(diphenylphosphine)ethane.

Hoke GD, McCabe FL, Faucette LF, Bartus JO, Sung CM, Jensen BD, Heys JR, Rush GF, Alberts DW, Johnson RK, et al.

Mol Pharmacol. 1991 Jan;39(1):90-7.

PMID:
1898982
38.

Phosphorothioate oligodeoxycytidine interferes with binding of HIV-1 gp120 to CD4.

Stein CA, Neckers LM, Nair BC, Mumbauer S, Hoke G, Pal R.

J Acquir Immune Defic Syndr. 1991;4(7):686-93.

PMID:
1711118
39.

Structural and functional studies of the rat mitochondrial single strand DNA binding protein P16.

Hoke GD, Pavco PA, Ledwith BJ, Van Tuyle GC.

Arch Biochem Biophys. 1990 Oct;282(1):116-24.

PMID:
2221914
40.

Mechanism of inhibition of rat liver mitochondrial respiration by oxmetidine, an H2-receptor antagonist.

Hoke GD, Cheng HY, Mirabelli CK, Rush GF.

J Pharmacol Exp Ther. 1990 Mar;252(3):908-14.

PMID:
1969477
41.

Immediate induction of c-fos and c-myc transcripts following unilateral nephrectomy.

Sawczuk IS, Olsson CA, Hoke G, Buttyan R.

Nephron. 1990;55(2):193-5.

PMID:
2113996
42.

In vivo and in vitro cardiotoxicity of a gold-containing antineoplastic drug candidate in the rabbit.

Hoke GD, Macia RA, Meunier PC, Bugelski PJ, Mirabelli CK, Rush GF, Matthews WD.

Toxicol Appl Pharmacol. 1989 Sep 1;100(2):293-306.

PMID:
2781559
43.

Gene expression in response to acute unilateral ureteral obstruction.

Sawczuk IS, Hoke G, Olsson CA, Connor J, Buttyan R.

Kidney Int. 1989 Jun;35(6):1315-9.

44.

Mechanism of toxicity of an experimental bidentate phosphine gold complexed antineoplastic agent in isolated rat hepatocytes.

Smith PF, Hoke GD, Alberts DW, Bugelski PJ, Lupo S, Mirabelli CK, Rush GF.

J Pharmacol Exp Ther. 1989 Jun;249(3):944-50.

PMID:
2732955
46.
47.
48.

Mechanism of alterations in isolated rat liver mitochondrial function induced by gold complexes of bidentate phosphines.

Hoke GD, Rush GF, Bossard GF, McArdle JV, Jensen BD, Mirabelli CK.

J Biol Chem. 1988 Aug 15;263(23):11203-10.

49.

The mechanism of acute cytotoxicity of triethylphosphine gold(I) complexes. II. Triethylphosphine gold chloride-induced alterations in mitochondrial function.

Rush GF, Smith PF, Hoke GD, Alberts DW, Snyder RM, Mirabelli CK.

Toxicol Appl Pharmacol. 1987 Sep 30;90(3):391-400.

PMID:
3660409
50.

Influence of dietary aflatoxin, zinc, and copper on bone size, organ weight, and body weight in hamsters and rats.

Llewellyn GC, Floyd EA, Hoke GD, Weekley LB, Kimbrough TD.

Bull Environ Contam Toxicol. 1985 Aug;35(2):149-56. No abstract available.

PMID:
4027418

Supplemental Content

Support Center